Skip to content

BridgeBio Pharma BBIO Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$729.89M-7.8%-$732.94M-34.9%-$805.69M-80.5%-$785.01M-70.1%-$676.8M-23.8%
$5.34M-7.4%$5.43M-10.6%$5.37M-14.7%$5.51M-13.9%$5.76M-10.7%
$140.38M+34.2%$133.02M+38.9%$128.51M+25.1%$120.41M+22.7%$104.63M+0.7%
-$443.95M-$445.91M-$584.82M-$655.81M
$1.17M+390%$1.1M+17.6%$1.11M-15.9%$778K-51.8%$238K-88.0%
$23.63M-62.8%$39.67M-38.5%
$48.28M
$837.01M$534.97M
$339.28M-$111.1M$237.22M
-$445.12M-$447.01M-$585.93M-$656.59M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does BridgeBio Pharma generate?
BridgeBio Pharma (BBIO) generated -$444.0M in operating cash flow over the trailing twelve months.
What is BridgeBio Pharma's free cash flow?
After $1.2M of capital expenditures, BridgeBio Pharma's free cash flow was -$445.1M over the trailing twelve months, up 44.0% year over year.
Where does BridgeBio Pharma's cash flow data come from?
Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.